OF
AKRO

Optimize Financial’s Akero Therapeutics AKRO Stock Holding History

Optimize Financial’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,920
Closed -$209K – 329
2025
Q2 		$209K Buy
+3,920
New +$178K 0.13% 211
2025
Q1 		– Sell
-8,336
Closed -$232K – 223
2024
Q4 		$232K Buy
+8,336
New +$252K 0.17% 181

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Optimize Financial's AKRO Position: Q3 2025 in Review

Optimize Financial sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 3,920 shares — an estimated $209K sold.

Optimize Financial first reported a position in AKRO in Q4 2024 and held it in 2 quarters. The position peaked at $232K in Q4 2024. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Optimize Financial reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Optimize Financial sold 3,920 Akero Therapeutics shares in Q3 2025, an estimated $209K.
  • Optimize Financial first reported a position in Akero Therapeutics in Q4 2024 and held it in 2 quarters.
  • Optimize Financial's Akero Therapeutics position peaked at $232K in Q4 2024.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Optimize Financial's 13F filing for Q3 2025, filed 5 Nov 2025.